ReviewIbrain2025
Prefrontal cortex iron content in neurodegeneration and healthy subjects: A systematic review.
Review in Ibrain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron accumulation in the prefrontal cortex (PFC) has been implicated in neurodegeneration and cognitive decline. Magnetic resonance imaging (MRI) enables noninvasive quantification of brain iron content and deposition. This review aimed to summarize the evidence on the MRI-based assessment of PFC iron accumulation in healthy individuals and patients with neurodegeneration. A systematic preliminary literature review was conducted using the PubMed, Scopus, Web of Science, and Embase databases. MRI techniques for capturing susceptibility changes reflecting iron, such as susceptibility-weighted imaging (SWI), quantitative susceptibility mapping (QSM), and R2* mapping, were included. Data were extracted, and narrative synthesis was performed. Twelve studies that measured PFC iron levels using MRI in diseases with neurodegeneration (five studies) and healthy subjects (seven studies) were included. In general, studies involving diseases with neurodegeneration have found that increased PFC iron content correlates with cognitive impairment. Aging studies on healthy subjects have reported that age-related accumulation of PFC iron, particularly in the dorsolateral, medial, and anterior subregions, increases with age, and is associated with reduced dopamine signaling and poorer cognition. MRI techniques, such as QSM, can quantify prefrontal iron accumulation in diseases with neurodegeneration and aging. As imaging biomarkers, increased prefrontal iron levels may contribute to neurodegeneration and cognitive decline. Longitudinal studies combining advanced QSM and other advanced neuroimaging techniques with cognitive assessments may further elucidate the effects of iron dysregulation on PFC function. Thus, our findings highlight the importance of MRI as a sensitive tool for assessing PFC iron content and its potential role in understanding the pathogenesis of neurodegeneration and the effects of aging on the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.